CN1241549C - 两性脂质体及其应用 - Google Patents

两性脂质体及其应用 Download PDF

Info

Publication number
CN1241549C
CN1241549C CNB028052137A CN02805213A CN1241549C CN 1241549 C CN1241549 C CN 1241549C CN B028052137 A CNB028052137 A CN B028052137A CN 02805213 A CN02805213 A CN 02805213A CN 1241549 C CN1241549 C CN 1241549C
Authority
CN
China
Prior art keywords
liposome
liposomes
amphoteric lipid
lipid body
amphoteric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028052137A
Other languages
English (en)
Chinese (zh)
Other versions
CN1492756A (zh
Inventor
斯特芬·潘茨纳
斯特凡·范克豪尼尔
弗朗克·埃斯勒
科妮莉亚·潘茨纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marina Biotech Inc
Original Assignee
Novosom AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novosom AG filed Critical Novosom AG
Publication of CN1492756A publication Critical patent/CN1492756A/zh
Application granted granted Critical
Publication of CN1241549C publication Critical patent/CN1241549C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB028052137A 2001-02-21 2002-02-21 两性脂质体及其应用 Expired - Fee Related CN1241549C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10109897.9 2001-02-21
DE10109897A DE10109897A1 (de) 2001-02-21 2001-02-21 Fakultativ kationische Liposomen und Verwendung dieser

Publications (2)

Publication Number Publication Date
CN1492756A CN1492756A (zh) 2004-04-28
CN1241549C true CN1241549C (zh) 2006-02-15

Family

ID=7675950

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028052137A Expired - Fee Related CN1241549C (zh) 2001-02-21 2002-02-21 两性脂质体及其应用

Country Status (11)

Country Link
US (4) US7371404B2 (enExample)
EP (1) EP1363601B1 (enExample)
JP (5) JP2004525898A (enExample)
CN (1) CN1241549C (enExample)
AT (1) ATE363893T1 (enExample)
AU (1) AU2002234643B2 (enExample)
BR (1) BRPI0207775B1 (enExample)
CA (1) CA2438116C (enExample)
DE (2) DE10109897A1 (enExample)
ES (1) ES2289079T3 (enExample)
WO (1) WO2002066012A2 (enExample)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10109897A1 (de) * 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
DE10207177A1 (de) * 2002-02-19 2003-09-04 Novosom Ag Fakultativ kationische Lipide
US7858117B2 (en) * 2002-02-21 2010-12-28 Novosom Ag Amphoteric liposomes and their use
CA2487274A1 (en) * 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
DE10255106A1 (de) * 2002-11-24 2004-06-09 Novosom Ag Liposomale Glucocorticoide
EP1547580A1 (en) * 2003-12-23 2005-06-29 MediGene Oncology GmbH Loading of a camptothecin drug into colloidal nanoparticles
DE102004054730A1 (de) 2004-03-28 2006-05-11 Novosom Ag Serumstabile amphotere Liposomen
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
AU2005300638A1 (en) * 2004-11-05 2006-05-11 Novosom Ag Improvements in or relating to pharmaceutical compositions comprising an oligonucleotide as an active agent
EP1764090A1 (en) * 2005-09-15 2007-03-21 Novosom AG Amphoteric liposomes for local drug applications
EP1811960A2 (en) * 2004-11-19 2007-08-01 Novosom AG Improvements in or relating to pharmaceutical compositions for local administration
EP1676569A1 (en) * 2004-12-30 2006-07-05 Pevion Biotech Ltd. Lyophilization of virosomes
EP1764091B1 (en) * 2005-09-15 2017-08-30 Marina Biotech, Inc. Improvements in or relating to amphoteric liposomes
US20120021042A1 (en) * 2005-09-15 2012-01-26 Steffen Panzner Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances
US20080088046A1 (en) * 2006-10-13 2008-04-17 Steffen Panzner Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
EP1911443A1 (en) * 2006-10-13 2008-04-16 Novosom AG Amphoteric liposomes, method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
EP1764089A1 (en) * 2005-09-15 2007-03-21 Novosom AG Serum stable liposomes comprising amphoter II lipid mixtures
EP1934348B1 (en) * 2005-10-11 2018-05-02 Ben-Gurion University Of The Negev Research And Development Authority Compositions for silencing the expression of vdac1 and uses thereof
US20090324587A1 (en) 2005-12-01 2009-12-31 Neal Clifford Goodwin Cancer Therapies and Pharmaceutical Compositions Used Therein
JP5122474B2 (ja) * 2005-12-01 2013-01-16 プロネイ・セラピューティクス・インコーポレイテッド 両性リポソーム製剤
ES2798263T3 (es) 2005-12-08 2020-12-10 Insmed Inc Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
WO2007117550A2 (en) * 2006-04-06 2007-10-18 Transave, Inc. Methods for coacervation induced liposomal encapsulation and formulations thereof
US20140178462A1 (en) * 2006-10-13 2014-06-26 Marina Biotech, Inc. Amphoteric liposomes comprising neutral lipids
AU2007306556B2 (en) * 2006-10-13 2014-04-10 Marina Biotech, Inc. Improvements in or relating to amphoteric liposomes
JP2010513354A (ja) * 2006-12-19 2010-04-30 ノヴォソム アクチェンゲゼルシャフト トランスフェクションエンハンサー要素を含む脂質および脂質集合体
WO2008118013A2 (en) 2007-03-23 2008-10-02 To-Bbb Holding B.V. Targeted intracellular delivery of antiviral agents
US20080260895A1 (en) * 2007-04-17 2008-10-23 Vermeire Drew A Milk replacer composition and product and method for producing the same
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
EP3434259A1 (en) 2007-05-04 2019-01-30 Marina Biotech, Inc. Amino acid lipids and uses thereof
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
DE102007029471A1 (de) 2007-06-20 2008-12-24 Novosom Ag Neue fakultativ kationische Sterole
WO2008154700A1 (en) 2007-06-20 2008-12-24 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith
EP2200586B1 (en) * 2007-09-07 2019-11-13 Synvolux IP B.V. Improved liposomes and uses thereof
CA2702103A1 (en) * 2007-10-12 2009-04-16 Novosom Ag Improvements in or relating to amphotaric liposomes comprising neutral lipids
WO2009149418A2 (en) * 2008-06-06 2009-12-10 Asuragen, Inc. Novel compositions for the in vivo delivery of rnai agents
CN104382853A (zh) 2008-10-16 2015-03-04 玛瑞纳生物技术有限公司 基因沉默治疗剂的脂质体有效递送方法和组合物
JP5392707B2 (ja) * 2009-03-31 2014-01-22 株式会社Ｎｔｔドコモ 膜小胞分裂システム
US20120107389A1 (en) * 2009-03-31 2012-05-03 Jayanta Bhattacharyya Amphoteric liposomal compositions for cellular delivery of small rna molecules for use in rna interference
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
ES2386855T3 (es) * 2009-07-09 2012-09-03 Marina Biotech, Inc. Emulación de estructuras de lipoproteínas
AU2010270337B2 (en) 2009-07-09 2016-09-22 Biontech Delivery Technologies Gmbh Amphoteric liposomes comprising imino lipids
SI2506857T1 (en) 2009-12-01 2018-08-31 Translate Bio, Inc. Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
WO2011120023A1 (en) 2010-03-26 2011-09-29 Marina Biotech, Inc. Nucleic acid compounds for inhibiting survivin gene expression uses thereof
WO2011133584A2 (en) 2010-04-19 2011-10-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting hras gene expression and uses thereof
WO2011139842A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2012159164A1 (en) 2011-05-23 2012-11-29 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
CN102532259A (zh) * 2012-03-09 2012-07-04 中国药科大学 基于寡肽的阳离子脂质衍生物及在药剂制剂中的应用
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
CN102603866B (zh) * 2012-03-15 2014-01-15 中国药科大学 基于寡肽的pH敏感型两性离子及其在药剂中的应用
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
PL2852391T3 (pl) 2012-05-21 2022-04-11 Insmed Incorporated Układy do leczenia infekcji płuc
EP3536787A1 (en) 2012-06-08 2019-09-11 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof
WO2013186793A1 (en) * 2012-06-11 2013-12-19 Council Of Scientific & Industrial Research Rice bran-lipids based formulation and process for preparation thereof for selective delivery of genes to cancer cells
AU2013340414B2 (en) 2012-10-23 2019-05-02 Caris Science, Inc. Aptamers and uses thereof
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
CN104884637A (zh) 2012-11-05 2015-09-02 普隆奈治疗公司 利用生物标志物通过bcl2表达的调节治疗癌症的方法
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
AU2013361323B2 (en) 2012-12-19 2018-09-06 Caris Science, Inc. Compositions and methods for aptamer screening
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
KR102311614B1 (ko) 2013-03-14 2021-10-08 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
WO2014143855A2 (en) 2013-03-15 2014-09-18 Mirna Therapeutics, Inc. Combination cancer treatments utilizing micrornas and egfr-tki inhibitors
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2016530232A (ja) 2013-06-24 2016-09-29 ミルナ セラピューティクス，インク． Ｍｉｒ−３４活性のバイオマーカー
JP5914418B2 (ja) 2013-06-26 2016-05-11 富士フイルム株式会社 脂質粒子、核酸送達キャリア、核酸送達キャリア製造用組成物、脂質粒子の製造方法及び遺伝子導入方法
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
ES2707966T3 (es) 2013-10-22 2019-04-08 Translate Bio Inc Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
EP3574923A1 (en) 2013-10-22 2019-12-04 Translate Bio, Inc. Mrna therapy for phenylketonuria
EP3126496A1 (en) 2014-04-01 2017-02-08 Mirna Therapeutics, Inc. Microrna dosing regimens
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
EP4729528A3 (en) 2014-04-25 2026-06-24 Translate Bio, Inc. Methods for purification of messenger rna
MX384843B (es) 2014-05-15 2025-03-14 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
JP6240570B2 (ja) 2014-07-17 2017-11-29 富士フイルム株式会社 脂質粒子および核酸送達キャリア
US10722599B2 (en) 2015-02-04 2020-07-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Lipid assemblies and uses thereof and some pH and electrostatic modulating lipids to be used in said assemblies
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
RS63051B1 (sr) 2015-12-22 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularnu isporuku agenasa
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
WO2018170322A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
IL270631B2 (en) 2017-05-16 2024-03-01 Translate Bio Inc Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
KR20200050982A (ko) * 2017-09-04 2020-05-12 이치마루 화루코스 가부시키가이샤 pH 감수성 리포솜 및 그 제조 방법
WO2019048645A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE
HRP20260181T1 (hr) * 2017-10-20 2026-03-27 BioNTech SE Priprema i skladištenje lipozomskih rnk formulacija koje su pogodne za terapiju
TW201936201A (zh) 2017-12-14 2019-09-16 美商堅固生物科技公司 基因之非病毒生產及遞送
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
US11566246B2 (en) 2018-04-12 2023-01-31 Mina Therapeutics Limited SIRT1-saRNA compositions and methods of use
EP3787602A4 (en) 2018-05-02 2022-03-23 Insmed Incorporated PROCESS FOR THE MANUFACTURE OF LIPOSOMAL DRUG FORMULATIONS
US20190381034A1 (en) * 2018-06-14 2019-12-19 Ming Fang Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
CA3110661A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
AU2019384557B2 (en) 2018-11-21 2025-07-17 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
EP3953473A1 (en) 2019-04-12 2022-02-16 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
AU2020351220A1 (en) 2019-09-19 2022-04-07 Modernatx, Inc. Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
EP4031524A1 (en) 2019-09-19 2022-07-27 ModernaTX, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
CA3155003A1 (en) 2019-09-20 2021-03-25 Translate Bio, Inc. Mrna encoding engineered cftr
US12115230B2 (en) 2020-04-09 2024-10-15 Verve Therapeutics, Inc. Base editing of ANGPTL3 and methods of using same for treatment of disease
WO2021255262A1 (en) 2020-06-19 2021-12-23 Sylentis Sau siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES
WO2022060871A1 (en) 2020-09-15 2022-03-24 Verve Therapeutics, Inc. Lipid formulations for gene editing
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
EP4015634A1 (en) 2020-12-15 2022-06-22 Sylentis, S.A.U. Sirna and compositions for prophylactic and therapeutic treatment of virus diseases
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
US20240175033A1 (en) 2021-03-26 2024-05-30 Mina Therapeutics Limited TMEM173 saRNA Compositions and Methods of Use
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
TW202440929A (zh) 2022-12-14 2024-10-16 加拿大商普羅維登斯治療控股公司 用於感染性疾病的組合物和方法
US20260218178A1 (en) 2022-12-22 2026-07-30 Mina Therapeutics Limited Chemically Modified saRNA Compositions and Methods of Use
IL321425A (en) 2022-12-23 2025-08-01 Biontech Delivery Tech Gmbh compound
KR20260065891A (ko) 2023-09-01 2026-05-11 노보아크 게엠베하 핵산 카고 및 이온화가능한 지질을 갖는 지질 나노입자
CN122535391A (zh) * 2023-12-22 2026-08-07 科蒂公司 用于将功能剂递送到皮肤的阳离子微囊泡和功能化外泌体样载体
WO2026027887A2 (en) 2024-08-02 2026-02-05 Mina Therapeutics Limited Hbg1/2-sarna compositions and methods of use

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599227A (en) * 1983-11-07 1986-07-08 Wisconsin Alumni Research Foundation Injectable pharmaceutical preparation for the induction of multiple follicular growth
US4891208A (en) 1985-04-10 1990-01-02 The Liposome Company, Inc. Steroidal liposomes
US5283122A (en) * 1984-04-19 1994-02-01 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
ATE45744T1 (de) 1984-07-25 1989-09-15 Ciba Geigy Ag Phosphatidylverbindungen, verfahren zu ihrer herstellung und ihre verwendung.
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5290563A (en) * 1989-07-27 1994-03-01 Laboratoire Des Stallergenes Method for combining a mixture of heterogeneous substances with liposomes
US5165994A (en) 1990-06-05 1992-11-24 University Of Delaware Spontaneous equilbrium surfactant vesicles
US5302389A (en) * 1992-08-17 1994-04-12 Board Of Regents, The University Of Texas System Method for treating UV-induced suppression of contact hypersensitivity by administration of T4 endonuclease
JP2950520B2 (ja) * 1993-04-02 1999-09-20 アンティキャンサー インコーポレーテド 毛胞に有益な配合物を送達する方法
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US5981501A (en) * 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US6258792B1 (en) * 1996-04-12 2001-07-10 University Of Pittsburgh Cationic cholesteryl derivatives containing cyclic polar groups
ES2165050T3 (es) * 1996-04-12 2002-03-01 Univ Pittsburgh Nuevos derivados cationicos de colesterilo que contienen grupos polares ciclicos.
EP0938298B1 (en) * 1996-09-13 2002-12-04 Lipoxen Technologies Limited Liposome-based composition
US7384923B2 (en) * 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes
US5962015A (en) * 1997-05-02 1999-10-05 Kobo Products S.A.R.L. Stabilized liposomes
CA2289702C (en) * 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
AU8525098A (en) * 1997-07-24 1999-02-16 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts
FR2766706B1 (fr) * 1997-07-30 2001-05-25 Biovector Therapeutics Sa Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation
US6106858A (en) * 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
JPH11302199A (ja) * 1998-04-16 1999-11-02 Sankyo Co Ltd 薬物運搬体を構成するグラフト共重合体
JP2000198731A (ja) * 1998-10-29 2000-07-18 Sankyo Co Ltd 毒性の低減されたリポソ―ム
DE19852928C1 (de) 1998-11-17 2000-08-03 Steffen Panzner Strukturen in Form von Hohlkugeln
US6379698B1 (en) * 1999-04-06 2002-04-30 Isis Pharmaceuticals, Inc. Fusogenic lipids and vesicles
DE10010264A1 (de) 2000-03-02 2001-09-13 Novosom Gmbh Stabilisierte Liposomen und Hüllstrukturen
DE10109897A1 (de) * 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
US7858117B2 (en) * 2002-02-21 2010-12-28 Novosom Ag Amphoteric liposomes and their use
EP1764091B1 (en) * 2005-09-15 2017-08-30 Marina Biotech, Inc. Improvements in or relating to amphoteric liposomes

Also Published As

Publication number Publication date
DE50210271D1 (de) 2007-07-19
US20070269504A1 (en) 2007-11-22
AU2002234643B2 (en) 2007-06-21
CA2438116C (en) 2011-10-11
WO2002066012A3 (de) 2002-12-19
ES2289079T3 (es) 2008-02-01
CN1492756A (zh) 2004-04-28
JP2011021026A (ja) 2011-02-03
US7780983B2 (en) 2010-08-24
JP5480764B2 (ja) 2014-04-23
US20070252295A1 (en) 2007-11-01
ATE363893T1 (de) 2007-06-15
US20030099697A1 (en) 2003-05-29
US20110293695A1 (en) 2011-12-01
BR0207775A (pt) 2004-03-30
EP1363601A2 (de) 2003-11-26
JP2004525898A (ja) 2004-08-26
JP2016104786A (ja) 2016-06-09
US7371404B2 (en) 2008-05-13
JP2014031383A (ja) 2014-02-20
EP1363601B1 (de) 2007-06-06
JP2014218520A (ja) 2014-11-20
WO2002066012A2 (de) 2002-08-29
DE10109897A1 (de) 2002-11-07
CA2438116A1 (en) 2002-08-29
BRPI0207775B1 (pt) 2015-10-20

Similar Documents

Publication Publication Date Title
CN1492756A (zh) 两性脂质体及其应用
US7858117B2 (en) Amphoteric liposomes and their use
JP4335310B2 (ja) 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
US5705385A (en) Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) Methods for encapsulating plasmids in lipid bilayers
JP6192061B2 (ja) 中性脂質を含む両性リポソーム
US20030077829A1 (en) Lipid-based formulations
US20060002991A1 (en) Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same
CN1349402A (zh) 生物活性络合物于脂质体中囊封工艺
JP2008501729A (ja) カチオン性脂質および使用方法
CN1444472A (zh) 质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中
CN1492876A (zh) 两性固醇及其应用
ES2561812T3 (es) Composición para inhibir la expresión de un gen diana
KR20140048404A (ko) 저밀도 지단백질 유사 나노입자 및 이를 포함하는 간 표적 진단 및 치료용 조성물
EP1867726A1 (en) Liposome capable of effective delivery of given substance into nucleus
Koynova et al. Recent patents in cationic lipid carriers for delivery of nucleic acids
KR20240123150A (ko) 지질결정 나노입자의 원스텝 제조방법, 이에 의해 제조되는 지질결정 나노입자 및 이의 용도
WO2026056650A1 (zh) 一种纳米递送载体及其制备方法
JP2006238839A (ja) 核酸の細胞内送達効率又は細胞内発現効率を向上させた組成物
WO2012117971A1 (ja) 脂質膜構造体、脂質膜構造体の製造方法および１の目的物質を１枚の脂質膜で封入する方法
AU7166700A (en) Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: MARINA BIOLOGICAL TECHNOLOGY CO., LTD.

Effective date: 20110824

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20110824

Address after: Washington, USA

Patentee after: Mdrna Inc.

Address before: Harley

Patentee before: Novosom AG

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060215

Termination date: 20170221